RMC No. 62-2025: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension, High Cholesterol, Mental Illnesses, and Tuberculosis

RMC No. 62-2025 updates VAT-exempt medicines for key diseases, requiring pharmacies and healthcare sellers to verify FDA publication and product tax codes. Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of covered medicines must immediately check the latest FDA-published VAT-exempt medicines list before issuing invoices, pricing products, or claiming VAT treatment. RMC No. 62-2025 confirms […]

RMC No. 59-2025: VAT-Exempt Medicines List Updated for Cancer, Diabetes, Hypertension, Kidney Disease, and Tuberculosis Products

RMC No. 59-2025 updates VAT-exempt medicines for key diseases, with effectivity tied to FDA Advisory issuance and proper product validation. Businesses dealing in medicines for cancer, diabetes, hypertension, kidney disease, and tuberculosis must immediately check whether their covered products are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration. RMC […]

RMC No. 68-2022: Updated VAT-Exempt Medicines List for Hypertension, Diabetes, Cancer, COVID-19 and Other Treatments

RMC No. 68-2022 updates the FDA-endorsed VAT-exempt medicines list under CREATE for key disease categories including COVID-19 and cancer. Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of medicines must check whether their covered products are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration, because qualifying medicines for hypertension, […]

RMC No. 2-2022: Updated VAT-Exempt COVID-19 Medicines Endorsed by DOH for Philippine Tax Compliance

RMC No. 2-2022 updates the list of VAT-exempt COVID-19 medicines under RA 11534, affecting pharmacies, hospitals, and suppliers. Businesses must adjust VAT treatment immediately. Businesses must now ensure their VAT compliance reflects the latest list of COVID-19 medicines that are exempt from value-added tax under Republic Act No. 11534. The Department of Health has officially […]

RMC No. 127-2021: VAT Exemption for Liraglutide Depends on Diabetes Use, Not Weight-Management Branding

RMC No. 127-2021 clarifies that Liraglutide is VAT-exempt only for diabetes management, while Saxenda for obesity or weight management is not covered. Businesses dealing with Liraglutide 6mg/mL Solution for Injection (SC) must not treat every sale or purchase of the product as automatically VAT-exempt. Under RMC No. 127-2021, the tax treatment turns on the product’s […]

RMC No. 34-2019: Input Tax Reporting Rules for VAT-Exempt Diabetes, High-Cholesterol, and Hypertension Medicines

RMC No. 34-2019 explains how sellers of VAT-exempt diabetes, cholesterol, and hypertension medicines must inventory stocks and adjust input tax. Manufacturers, wholesalers, distributors, and retailers holding unsold diabetes, high-cholesterol, and hypertension medicines as of December 31, 2018 had to inventory those medicines and adjust the related input VAT once the medicines became VAT-exempt beginning January […]

RMC No. 2-2019: VAT Exemption on Diabetes, High-Cholesterol and Hypertension Drugs in the Philippines

RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules. Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published […]